Zanzalintinib (XL092) plus nivolumab in non-clear cell renal cell carcinoma: The randomized phase 3 STELLAR-304 study.
Sumanta Kumar Pal(City Of Hope National Medical Center), Cristina Suárez(Vall d'Hebron Hospital Universitari), Mohan Liu(Bristol-Myers Squibb (United States)), Zhong Wang(Exelixis (United States)), Thomas Powles(Queen Mary University of London), Aarohi Bhatt(Exelixis (United States)), Pritesh Patel(Exelixis (United States)), Ravindran Kanesvaran(University of Ioannina)
Cited by 1
Related Papers
Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus
|Annals of Oncology|2020|313
The Identification of Plasma Exosomal miR-423-3p as a Potential Predictive Biomarker for Prostate Cancer Castration-Resistance Development by Plasma Exosomal miRNA Sequencing
|Frontiers in Cell and Developmental Biology|2021|64
Elderly patients with metastatic renal cell carcinoma: position paper from the International Society of Geriatric Oncology
|The Lancet Oncology|2018|62
Preliminary safety, pharmacokinetics and clinical activity of DFF332, an oral HIF2α inhibitor, as monotherapy in a phase 1 dose escalation study in patients with advanced clear cell renal cell carcinoma.
|Journal of Clinical Oncology|2024|9
Adjuvant Atezolizumab in Patients with Sarcomatoid Renal Cell Carcinoma: A Prespecified Subgroup Analysis of IMmotion010
|European Urology Oncology|2024|4